Please login to the form below

Not currently logged in
Email:
Password:

lung disease

This page shows the latest lung disease news and features for those working in and with pharma, biotech and healthcare.

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

to wait until their disease has progressed and lung function has deteriorated before they can get access to the drug. ... IPF is a progressive, irreversible and typically fatal lung disease characterised by scarring pf the lungs that makes breathing

Latest news

  • FDA panel rejects Aradigm/Grifols’ inhaled antibiotic FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

    Aradigm has been unable to convince an FDA advisory committee that that its inhaled version of ciprofloxacin should be approved for chronic infections in patients with a serious lung disease. ... NCFBE is a severe, chronic and rare disease characterised

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    COPD is a serious lung disease that affects millions of people, ”commented Eric Dube, head of GSK’s respiratory business unit.

  • Vertex's tezacaftor/ivacaftor shows lung function boost Vertex's tezacaftor/ivacaftor shows lung function boost

    Those treated with tezacaftor/ivacaftor also saw improvements across multiple disease measures, such as an improved lung disease, which is the leading cause of death in people with CF. ... It too met its primary endpoint, with a 6.8% increase in absolute

  • AZ starts pursuit of lung cancer indication for Imfinzi AZ starts pursuit of lung cancer indication for Imfinzi

    The company has moved swiftly ahead with the filing of Imfinzi (durvalumab) as a treatment of patients with locally-advanced (stage III), unresectable non-small cell lung cancer (NSCLC) whose disease ... Currently, the standard of care for patients with

  • Boehringer Ingelheim calls for Boehringer Ingelheim calls for "strong and united" Europe

    Crucially, while Boehringer's biggest drug Spiriva (tiotropium) for asthma and chronic obstructive pulmonary disease (COPD) started to face generic competition, other drugs offsetting its 14.9% decline to 3bn. ... In particular, Eli Lilly-partnered

More from news
Approximately 2 fully matching, plus 93 partially matching documents found.

Latest Intelligence

  • Significant figures Significant figures

    ALIS (Amikacin liposome inhalation suspension) is being developed as a treatment for refractory non tuberculous Mycobacterial (NTM) lung disease, a rare progressive, destructive infection caused by mycobacterium avium complex. ... However, Insmed

  • Pharma deals during August 2014 Pharma deals during August 2014

    lung scarring condition for which there are no approved drugs in the US. ... It also has potential utility in treating systemic sclerosis-related Interstitial Lung Disease.

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    for idiopathic pulmonary fibrosis (IPF) – a rare lung disease, characterised by by the formation of scar tissue within the lungs, that has nearly as bad a prognosis as lung cancer and ... This is in addition to nintedanib's potential as an oncology

  • Denmark: rising pharma spend amid healthcare cost-containment Denmark: rising pharma spend amid healthcare cost-containment

    Although patient choice is enshrined in law, care pathways particularly for cancer and heart disease were also created to ensure consistent treatment nationwide and reduce health inequalities. ... Thus, the top three causes of death in Denmark are

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    3. Coronary heart disease. 4. Lung cancer. 5. Stomach cancer. 6. ... Emergency care services are inundated with patients seeking routine treatments, and chronic disease management and preventative care are not so good.

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics